Compare Monster Beverage Corp (MNST) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs Novavax Inc — how do they compare? Monster Beverage Corp trades at $45.62 (market cap $89.20B), while Novavax Inc trades at $7.93 (market cap $1.31B). The key difference: Monster Beverage Corp is far larger — about 68.1× Novavax Inc's market cap, and Monster Beverage Corp is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| MNST | NVAX | |
|---|---|---|
Market Cap | $89.20B | $1.31B |
Sector | Consumer Staples | Health |
52-Week High | $49.97 | $11.19 |
52-Week Low | $30.86 | $6.22 |
Enterprise Value | $87.49B | $889.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $45.69, up 1.13% today. The stock shows strong fundamentals with Q2 2026 EPS of $0.60 beating estimates, driven by 20% revenue growth and a 23.08% net income margin. A 2-for-1 stock split occurred on August 11, 2026. However, technical indicators signal a bearish trend, with the current price below key resistance levels. Analyst consensus is bullish with a $51.14 price target, but high valuation ratios like a P/E of 42.16 pose risks.
Outlook: MNST's international expansion and earnings beats support growth, but stretched valuations and bearish technicals suggest near-term volatility. Investment opportunity lies in sustained profit margins, while risks include competitive pressures and premium pricing sensitivity.
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
